机构名称：
¥ 3.0
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condition, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results, the preliminary data of the B2151009 Phase 1b clinical trial, including its preliminary primary efficacy,安全性和耐受性数据以及其他未来条件。诸如但不限于“期待”，“相信”，“期望”，“预期”，“估计”，“打算”，“计划”，“计划”，“将”，“应该”，“应该”，“可以”，类似的表达方式或单词，以及确定前瞻性陈述。可能会不时出现新的风险和不确定性，并且无法预测所有风险和不确定性。本演讲中的任何前瞻性陈述均基于管理层当前的期望和信念，并受到许多风险，不确定性和重要因素，这些风险，可能导致实际事件或结果与任何前瞻性陈述所表达或暗示的风险或重要因素，包括本介绍中包含的任何前瞻性陈述，包括，包括，不受限制的风险，包括： trials, (ii) the fact that preliminary data from a clinical study may not be predictive of the final results of such study or the results of other ongoing or future studies, (iii) the success and timing of our product development activities and initiating clinical trials, (iv) expected partnership opportunities with pharmaceutical companies, (v) our ability to obtain and maintain regulatory approval of any of our product candidates, (vi) our plans to research, discover and develop additional product candidates, (vii) our ability to enter into collaborations for the development of new product candidates, (viii) our ability to meet any specific milestones set forth herein, and (ix) uncertainties and assumptions regarding the impact of the COVID-19 pandemic on Celcuity's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines.
使用第三代DX
主要关键词
相关文件推荐
